More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
ASCO 2024 movers – Affimed wins, Caribou loses
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
